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Cytochrome bc1 complexAtovaquone, a coenzyme Q analogue has been indicated to speciﬁcally target the cytochrome bc1 complex of the
mitochondrial respiratory chain in the malarial parasite and other protozoan. Various mutations in the quinone
binding site of the cytochrome b gene of Plasmodium spp. such as M133I, L144S, L271V, K272R, Y268C, Y268S,
Y268N, and V284F are suggesting to associate with resistance to atovaquone. There is no direct evidence of
relation between the mutations and resistance to atovaquone in Plasmodium parasite that has been available.
Technical difﬁculties in isolating active assayablemitochondria in themalarial parasite hinder us to obtain direct
biochemical evidence to support the relation between the mutations and drug resistance.
The establishment of a mitochondrial isolation method for themalaria parasite has allowed us to test the degree
of resistance of Plasmodium berghei isolates to atovaquone directly.We have tested the activity of dihydroorotate
(DHO)-cytochrome c reductase in various P. berghei atovaquone resistant clones in the presence of a wide
concentration range of atovaquone. Our results show the IC50 of P. berghei atovaquone resistant clones is much
higher (1.5 up to 40 nM) in comparison to the atovaquone sensitive clones (0.132–0.465 nM). The highest IC50
was revealed in clones carrying Y268C and Y268Nmutations (which play an important role in atovaquone resis-
tance in Plasmodium falciparum), with an approximately 100-fold increase. The ﬁndings indicate the importance
of the mutation in the quinone binding site of the cytochrome b gene and that provide a direct evidence for the
atovaquone inhibitory mechanism in the cytochrome bc1 complex of the parasite.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The expansion of drug-resistant strains of Plasmodium falciparum has
caused serious global health problems inmalaria treatment. Several new
drugs have been introduced including new derivatives of quinoline-
based compounds, but resistance of the parasite to those drugs devel-
oped very rapidly [1]. Different biochemical pathways in the malaria
parasite are needed as the pharmacological target for the new affordable
drugs.
Ubiquinone is a coenzyme involved in the mitochondrial electron
transport, and serves as a point of contact between pyrimidine
metabolism and energy metabolism. Atovaquone (a hydroxy-1,4-Chemistry, Graduate School of
yo-ku, 113-0033Tokyo, Japan.
and Ltd. This is an open access article unaphthoquinone derivative), that shares structural similarity with
ubiquinone, has been suggested to be a potent and speciﬁc inhibitor of
the parasite cytochrome bc1 complex, and its molecular target is
known to be the ubiquinol oxidation pocket (Qo site) of the cytochrome
bc1 complex [2–4]. The drug has a broad spectrum activity against vari-
ous apicomplexan parasites andmutations in the cyt b genewere shown
to associate with resistance to atovaquone in various organisms, such as
Plasmodium species, Toxoplasma, Pneumocystis jirovecii and yeast [5–11].
However, no direct evidence of relation between the mutations and
resistance has been available by using intact mitochondria isolated
from the malarial parasite, although biochemical analysis of the mutant
has been reported using cell free extract [12].
Our group has reported various mutations in the quinone binding
site of the cyt b gene of Plasmodium berghei such as M133I, L144S,
L271V, K272R, Y268C, Y268S, Y268N, and V284F by using the mouse
model with continuous atovaquone pressure [5,13] and all of those
mutations have been proven to associate with resistance to atovaquonender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tivemitochondria in themalarial parasite hinder us to obtain direct bio-
chemical evidence to support the aforementioned results.
Following the establishment of themitochondrial isolationmethod in
the malaria parasite [14], we further tested the activity of dihydroorotate
(DHO)-cytochrome c reductase in various P. berghei atovaquone resistant
and sensitive clones in the presence of a wide concentration range
of atovaquone for the sensitivity of the enzymes to the drug which
might be altered by the cytochrome bmutations. We found that muta-
tions in the quinone binding site of the cytochrome b gene resulted in
a various sensitivity to atovaquone and provide a direct evidence for
the atovaquone inhibitory mechanism in the parasite cytochrome bc1
complex.2. Material and method
2.1. Malaria parasites
P. berghei ANKA strains from Leiden through the gift of Dr. Andy
Waters, Leiden University Medical Center, Netherland were used
throughout this study.
Atovaquone-resistant mutant isolates were derived from P. berghei
ANKA strain in the previous study [5,13] with different mutations in
the cytochrome b (PbLSJ2 with Y268C; PbLSJ3 with L271V, K272R;
PbLSJ1 with Y268N; PbSK2A1T with M133I, V284F; PbSK2A1Tb with
M133I, L271V; PbSK1A2with V284F; and PbSR1 with L144S, V284F).
The parasites weremaintained by serial blood passage and inoculated
intraperitoneally into 10- to 12-week-old BALB/c mice at approximately
106 parasitized red blood cells/mouse. The parasitemia from several ran-
dom mice were examined every two days until giving raise to 40–50%
parasitemia.2.2. Antimalarial drugs
Atovaquone was kindly provided by Dr. Mary Pudney of the
Wellcome Research Laboratories, UK. A 10−2 M stock solution was
dissolved in dimethyl sulfoxide and stored at−20 °C.2.3. Preparation of mitochondrial fraction
Aprotocol to prepare activemitochondria frommouceblood infected
with P. bergheiwas established as described below with a slight modiﬁ-
cation from the protocol for P. falciparum[14].2.3.1. Isolation and puriﬁcation of erythrocytes
Mouse blood infected with P. berghei parasites (7–8 days post infec-
tion with 40–50% parasitemia) was collected by cardiac puncture using
a sterile disposable syringe and transferred into heparinized tube. Sub-
sequently, platelet rich plasma and white blood cells were removed by
the addition of 1/10 volume of 3.8% sodium citrate and 0.027 M NaCl
to the tube, and then the solution was mixed gently and centrifuged at
800 g for 10 min [TOMY LX-120 (TOMY SEIKO Co Ltd, Japan)]. The
supernatant including buffy coat (whitish layer: about 1/3 portion
from the top of pellet) was discarded by Pasteur pipette. Ten volumes
of 0.85% NaCl containing 4% dextran were added to the pellet, mixed
gently and followed by centrifugation at 20 g for 10 min to remove
the remaining white blood cells. The suspension follows a ﬁltration
through a leucoﬁlter (Sepacell RN-10 Asahi Medical Co Ltd, Japan)
that was pre-equilibrated with phosphate-buffered saline (PBS;
0.14 M NaCl, 0.01 M Na2HPO4; pH 7.2). Filtrate was centrifuged at
1750 g for 10 min to collect pure erythrocytes.
Animal care and experimental procedureswere performed according
to the Guidelines for Animal Experiments, The University of Tokyo.2.3.2. Isolation of P. berghei mitochondria from infected erythrocytes
The pure parasite-infected erythrocytes were harvested and treated
with 0.15% (w/v) saponin in PBS. After washingwith PBS, the cells were
disrupted with N2 cavitation method using Cell Disruption Bomb (Parr
Instrument Company, USA) at 1200 psi for 15 min at 4 °C in 5 volumes
of H-medium (210 mM mannitol, 70 mM sucrose, 1 mM EGTA, 5 mM
MgCl2, 4 mM HEPES, 5 mM KH2PO4; pH 7.2) supplemented with 0.1%
BSA, 1 mM PMSF and protease inhibitor cocktail (component of prote-
ase inhibitor cocktail: 2 mM AEBSF, 1 mM EDTA, 130 μM Bestatin,
14 μM E-64, 1 μM Leupeptin and 0.3 μM Aprotonin). Unbroken cells
and cell debris were removed by centrifugation at 700 g for 8 min at
4 °C. The mitochondrial fraction was then recovered as a precipitate
by centrifugation at 10,000 g for 10 min at 4 °C.
2.4. Enzyme assay
Since the activity of the Plasmodium bc1 complex was too low
for kinetic study of the enzyme, we measured the activity of DHO-
cytochrome c reductase, which is more reliable than the ubiquinol-
cytochrome c assay. DHO-cytochrome c activity consists of two
enzymes, dihydroorotate dehydrogenase (DHODH) and bc1 complex
(Fig. 1). DHODH and DHO-cytochrome c reductase activities using
dichlorophenol indophenol (DCIP) and cytochrome c as an electron
acceptor, respectively, from various atovaquone-resistant and -sensitive
P. berghei clones were measured in the presence of a wide concentration
range of atovaquone.
2.4.1. DHODH activity
Spectrophotometric enzyme assay was performed using ubiquinone-
2 and DCIP as electron acceptors [15]. DHODH activity was measured by
recording the absorbance change of DCIP at 600 nm (UV-3000 spectro-
photometer; Shimazu, Japan), following the addition of 500 μM DHO to
30 mM Tris–HCl (pH 8.0), 74 μg/ml DCIP, 100 μM ubiquinone-2 and
2 mM KCN at 25 °C.
2.4.2. DHO-cytochrome c reductase activity
DHO-cytochrome c reductase activity was measured by recording
the change in absorbance of cytochrome c at 550 nm following the ad-
dition of 500 μM DHO to 30 mM Tris–HCl (pH 8.0), 20 μM cytochrome
c and 2 mM KCN. In this system, electrons from DHO are transferred
to ubiquinone by DHODH, and then ﬁnally transferred to cytochrome
c by bc1 complex.
2.5. Molecular modeling
Since atovaquone is smaller in molecular size than stigmatellin but
relatively similar to 5-n-heptyl-6-hydroxy-4,7-dioxobenzothiazole
(HHDBT), we have referred to the crystal structure of yeast cytochrome
bc1 complexedwith HHDBT as shown in Fig. 2. Molecularmodelingwas
carried out on NEC workstations, starting with the X-ray structure of
yeast cytochrome bc1 complexedwithHHDBT (pdbID: 1P84). Structural
parameters of atovaquone were calculated with the Dundee PRODRG2
server (http://davapc1.bioch.dundee.ac.uk/prodrg/). Atovaquonemole-
cule was manually aligned in the same manner of HHDBT with the
graphic programO [16]. Themolecular dynamics and continuous energy
minimization were calculated with the CNS software [17].
3. Result and discussions
In the present study, we directly showed that P. berghei resistant to
antimalarial drug atovaquone was attributed to the mutations of mito-
chondria cyt b gene at the Qo site. Mutations M133I and L271V, and
mutation Y268N show speciﬁc activity about half of the wild type
isolate, indicating that there may be a little defect in the respiratory
function. Other mutant isolates show similar activities to the wild
type. The ﬁndings may be associated with the fact that there are some
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Fig. 1. Role of mitochondrial respiratory chain in malaria parasite. Respiratory chain of Plasmodium is composed from active complex II (succinate-ubiquinone reductase), III (quinol-
cytochrome c reductase), IV (cytochrome c oxidase) and dihydroorotate dehydrogenase (DHODH). Ubiquinone (UQ) or commonly called coenzyme Q plays an important role in the
respiratory chain of Plasmodiummitochondria. It is a point of contact between pyrimidine metabolism and energy metabolism. Many antimalarial agents contain a quinone structure.
The enzymes mediating electron transfer between the enzymes and ubiquinone are considered to be good targets.
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Plasmodium enzyme.
Directmeasurement of ubiquinol-cytochrome c reductase activity in
Plasmodium cytochrome bc1 complex is difﬁcult because the activity of
Plasmodium enzyme is too low to estimate and signiﬁcant non-
enzymatic redox reaction between ubiquinol and cytochrome c could
not be eliminated. Therefore, we measured the activity of DHO-
cytochrome c reductase (composed of DHODH, endogenous ubiquinone
and cytochrome bc1 complex; Fig. 1), which allowed us to obtain repro-
ducible data by showing constant cytochrome c reduction during the
measurement with negligible non-enzymatic reaction.
To ascertain that the atovaquone speciﬁcally inhibited the bc1
complex, the DHODH activity in the presence of atovaquone was(a)
(b)
(c)
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Fig. 2. Chemical Structures of Qo site inhibitors. (a) Atovaquone, (b) stigmatellin, and
(c) 5-n-heptyl-6-hydroxy-4,7-dioxobenzothiazole (HHDBT).independently measured ﬁrst. The DHODH activity was not affected
by atovaquone at doses up to 100 μM indicating that atovaquone sensi-
tivity of bc1 complex can be examined bymeasuring DHO-cytochrome c
reductase activity of the mitochondria. Speciﬁc activities of DHO-
cytochrome c reductase from the atovaquone mutant isolates and the
wild type are shown in Table 1. The data obtained in this study
highlighted variations in speciﬁc activities of enzyme and IC50 to
atovaquone, which explain the difference in atovaquone sensitivity.
Themutation sites acquiring resistance to atovaquonewere all local-
ized to the Qo site and classiﬁed into three groups on the basis of
acquired IC50 values. All of the mutant mitochondria showed higher
IC50 values (1.45–43.5 nM) than that of wild type (0.327 nM). The
highest IC50 was found in clones carrying the Y268C or Y268N
mutations with an approximately 100 fold increase, 42.5 and 43.5 nM,
respectively. The L271V/K272R, and M133I/L271V mutations had a
slightly moderate effect, with IC50 values around 20 nM. The M133I/
V284F, L144S/V284F and V284F mutations exhibited the lowest but
signiﬁcant effect, with IC50 values between 1.45 and 7.2 nM.
Although there are many X-ray structures of cytochrome bc1
complexes from different organisms available [18–22], the mechanism
of quinol oxidation has been discussed based on the inhibitor bound
structures due to the lack of the complex structure with ubiquinol at
Qo site. Among the cytochrome bc1 complex 3-D structures available
in the database, the yeast complex has the highest similarity to those
of apicomplexan parasites, especially around the ubiquinol oxidation
pocket at the Qo site (61% identical in amino acid sequence). Two
high-resolution crystal structures complexed with Qo site inhibitor,
stigmatellin and HHDBT have been reported [21,23]. Reaction mecha-
nism of ubiquinol oxidation in bifurcated manner transferring
two electrons to the [2Fe–2S] cluster and heme bL has been discussedTable 1
Inhibitory effect of atovaquone against DHO-cytc activity.
Isolates Atovaquone⁎ Mutation Speciﬁc activity
(nmol/mg/min)
IC50 (nM)
P. falciparum S – 2.56 0.052
P. berghei L (PbL) S – 22.7 0.327 ± 0.141
PbLSJ2.1 R Y268C 22.4 42.5 ± 5.9
PbLSJ1.1 R Y268N 13.0 43.5 ± 3.9
PbLSJ3.1 R L271V, K272R 20.4 19.5
PbSK2A1Tb R M133I, L271V 13.0 20.0
PbSK2A1T R M133I, V284F 6.17 ± 0.7
PbSK1A2⁎⁎ R V284F 26.5 1.45
PbSR-1⁎⁎ R L144S, V284F 18.5 7.2
⁎ S represents for sensitive parasite while R for resistant parasite.
⁎⁎ These isolates were reported previously by Syafruddin et al.[5].
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of HHDBT and stigmatellin bindings at the Qo site based on the
yeast X-ray structures has been proposed [21].
It was desirable to have the crystal structure of cytochrome bc1 from
the malaria parasites, but is obviously difﬁcult to get the crystals of
them. Yeast bc1 variants, to which atovaquone-resistance mutations
found in the malarial parasites are introduced, revealed that their rela-
tive increase in IC50 correlated with that in calculated atovaquone-
binding energy [10]. Molecular basis for atovaquone resistance in
P. jirovecii has also been proposed based on the homology model in
the yeast cytochrome bc1 complex [24,25]. In our case, based on the
directly measured IC50 values of Plasmodium enzymes and the energy
minimized docking model, the binding mode of atovaquone was
revealed to be similar to that of HHDBT to the yeast cytochrome bc1.
In the yeast crystal structure, the oxygen atom of O6 from HHDBT
forms hydrogen bond to His181 of the Rieske iron–sulfur protein (ISP)
and Tyr279 of the cyt b at the Qo site [23]. Since atovaquone has similar
oxygen atom of O6 at the hydroxynaphthoquinone head group, it may
form the hydrogen bond to His181 of malaria ISP in the same manner.
It was reasonable to presume that the head group of atovaquone
bound to the back of Qo site analogously to that of HHDBT and the
chlorophenyl ring extends to the portal of Qo site. The same hydrogen
bond of atovaquone to His181 has been observed by electron paramag-
netic resonance (EPR) spectrum in the yeast bc1 complex [24].
We have investigated atovaquone binding mode at the Qo site of
malaria cytochrome b based on the IC50 values of atovaquone-
resistant variants and the available homologous 3D structures. It is
clear that Tyr268 is very important for atovaquone binding at the Qo
site as evidenced by the highest IC50 value. In the yeast crystal struc-
tures, the corresponding Tyr279 is involved in the binding of stigmatellin
and HHDBT, and provides a week CH–O hydrogen bond to inhibitors
(Fig. 3a, b) [23]. Atovaquonemight also need Tyr268 for a CH–Ohydrogen
bonding to stabilize the head group in the Qo site. It should be noted thatI299
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Fig. 3. Active site structure of the S. cerevisiae cytochrome b complexed with HHDBT (pdb:1P8
(b) Qo site of the yeast cytochrome b showing the residues interacting with HHDBT. (c) Qo siteIC50 of Y268C was 42.5 nM for P. berghei, while the equivalent yeast
variant, Y279C, was between 1 and 2 μM [10].
The Leu282 and Arg283 in the yeast cytochrome b, which correspond
to Leu271 and Lys272 in the malaria cyt b, localized to the vicinity of
Tyr279 residue in the yeast 3-D structure (Fig. 3c). The Leu271 and
Lys272 mutations conferred a 50 fold increase in resistance to
atovaquone based on the IC50 value, but mutation in the corresponding
residues in yeast cytochrome bc1 apparently did not affect the HHDBT
binding [23]. The resistance caused by Arg272 is also observed by muta-
tional analysis in Rhodobacter capsulatus. Sensitivity to atovaquone in-
creased 3 fold by I304M and R306K double mutations in R. capsulatus,
which corresponds to the sequence conversion from Saccharomyces
cerevisiae to P. berghei at Met270 and Lys272[26]. It therefore suggests
that these two residues might be responsible for the speciﬁc binding
of atovaquone to the malarial cytochrome bc1. The positions of these
residues are at the opposite to the presumed interacting region of
atovaquone head group within Qo site (Fig. 3b, c). Obvious difference
in the chemical structures of atovaquone and HHDBT lies between the
relatively inﬂexible cyclohexyl–chlorophenyl side-chain and the simple
alkyl chain of HHDBT (Fig. 2). The cyclohexyl–chlorophenyl side chain
might speciﬁcally interact with the residues from ef- to F-helices includ-
ing Leu271 and Lys272, and consequently increased the binding afﬁnity of
atovaquone to the cytochrome b (Fig. 4). Thus, ef-helix, which contains
Tyr268 and Leu271, is the key domain for atovaquone resistance.
The M133I mutation had certainly affected the resistance to
atovaquone. The corresponding Met139 in the yeast structure has van
der Waals interactions with the tip of HHDBT at the back side of Qo
site (Fig. 3b, c). Atovaquone is expected to bind in the same manner as
discussed above. The mutation of Met133 to Ile with branched side
chain at this point might only affect the inhibitor binding. The Leu144
and Val284 mutations conferred a feeble resistance to atovaquone. The
mutations were localized to the portal of Qo site and might hinder
atovaquone from smoothly entering the Qo site, because the head90°
90°
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4). (a) Schematic representation of the cytochrome b extracted from the whole complex.
showing the distribution of atovaquone resistant mutational sites.
Fig. 4. Sequence alignment of the cytochrome b residues consisting of the Qo site. Secondary structure informations are deduced from S. cerevisiae structure. +: residues involved in
stigmatellin binding, *: residues involved in HHDBT binding, X: atovaquone resistance mutation sites in this study. Accession numbers are: S. cerevisiae, P03873; P. jirovecii, AFV57344;
Bos taurus (B. taurus), CAA24007; P. berghei, O99253.
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functional groups (Fig. 3c).
Comparison between the inhibitionmechanism based on the crystal
structure complexed with inhibitor and the actual IC50 value is helpful
in elucidating the functions of active site residues during quinol oxida-
tion by the cytochrome bc1 complex. The residues interacting with
HHDBT in the yeast cytochrome bc1 structure, Trp142, Gly143, Ile269,
Pro271 and Tyr279, have been proven to be important for ubiquinol oxi-
dation by the pointmutation analysis [27,28]. By aligning the conserved
region of cyt b between yeast and malaria parasite, atovaquone-
resistant clones in the malaria parasites do not carry those correspond-
ing four mutations (Trp142, Gly143, Ile269, Pro271) except for yeast Tyr279.
Therefore, the basic mechanism of quinol oxidation in themalaria cyto-
chrome bc1 seems not similar to that in the yeast bc1 complex. In this
study, it became clear that the mechanism of atovaquone inhibition at
the Qo site of malaria cytochrome bc1 complex could not be modeled
based on the previous results in yeast or photosynthetic bacteria.
Malaria parasites may devise a strategy to ﬁnely tune an ubiquinol
oxidation in their mitochondria. The ﬁndings indicate the importance
of themutation in the quinone binding site of the cyt b gene and provide
a direct evidence for the atovaquone inhibitory mechanism in the
parasite cytochrome bc1 complex.
4. Note added in proof
During the revision of this manuscript, a report on the co-crystal
structure analysis of yeast bc1 complex with atovaquone has been ap-
peared (Nature Comm., DOI: http://dx.doi.org/10.1038/ncomms5029).
The crystal structure is quite similar to that of our hypothetical binding
model of bound atovaquone to yeast bc1 complex. Althoughmost of the
data described in the paper are consistent with our result, we need to
be careful in discussing the atovaquone inhibitory mechanism in the
Plasmodium cytochrome bc1 complex based on the model systems
such as yeast and bacterial enzymes as shown in our present study.
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